Advertisement

Review of methodological issues of clinical trials in multiple sclerosis

  • Xavier Montalban
    Correspondence
    Correspondence: Dr. Xavier Montalban, Unit of Clinical Neuroimmunology, EUI-2a P, Hospital Universitari Vall d'Hebron, Paseig Vall dHebron 119129, 08035 Barcelona, Spain
    Affiliations
    Unitat de Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat), Hospital Universitari Vall d'Hebron, Barcelona, Spain
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Summary

      There are currently six approved disease-modifying therapies available to the physician for the treatment of multiple sclerosis. Their efficacy on clinical and radiological parameters has been demonstrated in Phase III pivotal clinical trials over the past two decades. Perceptions of the relative potency of these treatments have been driven principally by the response measured relative to a placebo group. However, efficacy comparisons between trials is of limited value because of differences in study methodology, in characteristics of the patient populations included, in the behaviour of the placebo group during the trial and in the time at which the trial was conducted. Moreover, and most importantly, the assumption that the efficacy observed in clinical trial settings is the same as that achievable in everyday clinical practice is inevitably flawed. Impressions of the relative efficacy of two treatments may differ dramatically depending on whether absolute or relative differences with respect to placebo are compared. Randomised direct comparative trials are therefore the only objective way to evaluate the relative efficacy of two therapies. It is clear that between-treatment differences are difficult to quantify in short-term studies and require large numbers of patients. Long-term outcome is increasingly important to monitor in spite of the inherent methodological limitations in order to establish the safety profile of a potentially lifelong treatment. New disease-modifying treatments for multiple sclerosis will soon be available. Although these are eagerly awaited, their risk–benefit profile, and their place in therapy, will only be adequately understood once real-life and long-term use has been documented as well as it has been for current treatments.
      Over the last two decades, considerable advances have been made in the methodology of clinical trials in multiple sclerosis. Consensual standardised protocols have been designed and validated for Phase II and Phase III trials, with standardised definitions for short-term clinical and radiological outcome measures. The elaboration and implementation of this methodology were possible through international collaborations, and this has enabled extensive experience to be gained throughout the world. These trials have laid the foundation for an evidence-based medicine approach to the treatment of multiple sclerosis.
      Clinical trials in multiple sclerosis have to some extent become a victim of their own success, with more and more trials competing for a limited pool of patients and limited resources. Modern trials require large number of patients to generate adequate statistical power and this in turn entails recruitment in many countries across different continents. This increases the complexity and cost of the study, and contract research organisations now play a dominant role in the logistics and administration of these trials.
      The challenge in conducting trials on a global basis involving large numbers of countries is to ensure that this heterogeneity does not impinge on the reliability of the findings. This may happen due to differences in the patient populations included in different countries, access to or experience with methods in evaluation, for example certain magnetic resonance imaging (MRI) protocols, and also due to ethical considerations. In addition, whether disease-modifying treatments are reimbursed in a given country or not will influence what sort of patients are likely to get included in clinical trial protocols.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Panitch H
        • Miller A
        • Paty D
        • Weinshenker B
        Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
        Neurology. 2004; 63: 1788-1795
        • European Study Group on interferon beta-1b in secondary progressive MS
        Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis.
        Lancet. 1998; 352: 1491-1497
        • SPECTRIMS Study Group
        Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results.
        Neurology. 2001; 56: 1496-1504
        • Cohen JA
        • Cutter GR
        • Fischer JS
        • Goodman AD
        • Heidenreich FR
        • Kooijmans MF
        • et al.
        Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
        Neurology. 2002; 59: 679-687
        • Rovaris M
        • Confavreux C
        • Furlan R
        • Kappos L
        • Comi G
        • Filippi M
        Secondary progressive multiple sclerosis: current knowledge and future challenges.
        Lancet Neurol. 2006; 5: 343-354
        • Hartung HP
        • Gonsette R
        • Konig N
        • Kwiecinski H
        • Guseo A
        • Morrissey SP
        • et al.
        Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
        Lancet. 2002; 360: 2018-2025
        • Benson K
        • Hartz AJ
        A comparison of observational studies and randomized, controlled trials.
        N Engl J Med. 2000; 342: 1878-1886
        • Concato J
        • Shah N
        • Horwitz RI
        Randomized, controlled trials, observational studies, and the hierarchy of research designs.
        N Engl J Med. 2000; 342: 1887-1892
        • Juni P
        • Altman DG
        • Egger M
        Systematic reviews in health care: Assessing the quality of controlled clinical trials.
        BMJ. 2001; 323: 42-46
        • Shrier I
        • Boivin JF
        • Steele RJ
        • Platt RW
        • Furlan A
        • Kakuma R
        • et al.
        Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles.
        Am J Epidemiol. 2007; 166: 1203-1209
        • Johnson KP
        • Brooks BR
        • Cohen JA
        • Ford CC
        • Goldstein J
        • Lisak RP
        • et al.
        Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
        Neurology. 1995; 45: 1268-1276
        • Ford C
        • Goodman AD
        • Johnson K
        • Kachuck N
        • Lindsey JW
        • Lisak R
        • et al.
        Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.
        Mult Scler. 2010; 16: 342-350
        • Giovannoni G
        • Comi G
        • Cook S
        • Rammohan K
        • Rieckmann P
        • Soelberg Sorensen P
        • et al.
        A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
        N Engl J Med. 2010; 362: 416-426
        • Koch-Henriksen N
        • Sorensen PS
        The changing demographic pattern of multiple sclerosis epidemiology.
        Lancet Neurol. 2010; 9: 520-532
        • Bentzen J
        • Flachs EM
        • Stenager E
        • Bronnum-Hansen H
        • Koch-Henriksen N
        Prevalence of multiple sclerosis in Denmark 1950–2005.
        Mult Scler. 2010; 16: 520-525
        • Schumacker GA
        • Beebe G
        • Kibler RF
        • Kurland LT
        • Kurtzke JF
        • McDowell F
        • et al.
        Problems of experimental trials of therapy in multiple sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis.
        Ann N Y Acad Sci. 1965; 122: 552-568
        • Poser CM
        • Paty DW
        • Scheinberg L
        • McDonald WI
        • Davis FA
        • Ebers GC
        • et al.
        New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
        Ann Neurol. 1983; 13: 227-231
        • McDonald WI
        • Compston A
        • Edan G
        • Goodkin D
        • Hartung HP
        • Lublin FD
        • et al.
        Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
        Ann Neurol. 2001; 50: 121-127
        • Polman CH
        • Reingold SC
        • Edan G
        • Filippi M
        • Hartung HP
        • Kappos L
        • et al.
        Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”.
        Ann Neurol. 2005; 58: 840-846
        • Montalban X
        • Tintore M
        • Swanton J
        • Barkhof F
        • Fazekas F
        • Filippi M
        • et al.
        MRI criteria for MS in patients with clinically isolated syndromes.
        Neurology. 2010; 74: 427-434
        • Feinstein AR
        • Sosin DM
        • Wells CK
        The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.
        N Engl J Med. 1985; 312: 1604-1608
        • Sormani MP
        • Tintore M
        • Rovaris M
        • Rovira A
        • Vidal X
        • Bruzzi P
        • et al.
        Will Rogers phenomenon in multiple sclerosis.
        Ann Neurol. 2008; 64: 428-433
        • Inusah S
        • Sormani MP
        • Cofield SS
        • Aban IB
        • Musani SK
        • Srinivasasainagendra V
        • et al.
        Assessing changes in relapse rates in multiple sclerosis.
        Mult Scler. 2010; 16: 1414-1421
        • Freedman MS
        • Hughes B
        • Mikol DD
        • Bennett R
        • Cuffel B
        • Divan V
        • et al.
        Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
        Eur Neurol. 2008; 60: 1-11
        • Jacobs LD
        • Cookfair DL
        • Rudick RA
        • Herndon RM
        • Richert JR
        • Salazar AM
        • et al.
        Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
        Ann Neurol. 1996; 39: 285-294
        • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
        Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.
        Lancet. 1998; 352: 1498-1504
        • The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group
        Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
        Neurology. 1993; 43: 655-661
        • Polman CH
        • O'Connor PW
        • Havrdova E
        • Hutchinson M
        • Kappos L
        • Miller DH
        • et al.
        A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
        N Engl J Med. 2006; 354: 899-910
        • Kappos L
        • Radue EW
        • O'Connor P
        • Polman C
        • Hohlfeld R
        • Calabresi P
        • et al.
        A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
        N Engl J Med. 2010; 362: 387-401
        • Mikol DD
        • Barkhof F
        • Chang P
        • Coyle PK
        • Jeffery DR
        • Schwid SR
        • et al.
        Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
        Lancet Neurol. 2008; 7: 903-914
        • O'Connor P
        • Filippi M
        • Arnason B
        • Comi G
        • Cook S
        • Goodin D
        • et al.
        250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study.
        Lancet Neurol. 2009; 8: 889-897
        • Cohen JA
        • Barkhof F
        • Comi G
        • Hartung HP
        • Khatri BO
        • Montalban X
        • et al.
        Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
        N Engl J Med. 2010; 362: 402-415
        • National Institute for Clinical Excellence
        Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. NICE, London2007
        • Inglese M
        MRI measures of neuroprotection and repair in multiple sclerosis.
        J Neurol Sci. 2011; 311: S16-S23
        • Bielekova B
        • Richert N
        • Howard T
        • Blevins G
        • Markovic-Plese S
        • McCartin J
        • et al.
        Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
        Proc Natl Acad Sci U S A. 2004; 101: 8705-8708
        • Bielekova B
        • Catalfamo M
        • Reichert-Scrivner S
        • Packer A
        • Cerna M
        • Waldmann TA
        • et al.
        Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
        Proc Natl Acad Sci U S A. 2006; 103: 5941-5946
        • Havrdova E
        • Galetta S
        • Stefoski D
        • Comi G
        Freedom from disease activity in multiple sclerosis.
        Neurology. 2010; 74: S3-S7
        • Hartung HP
        New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
        Lancet Neurol. 2009; 8: 28-31
        • Marriott JJ
        • Miyasaki JM
        • Gronseth G
        • O'Connor PW
        Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
        Neurology. 2010; 74: 1463-1470